Impress
PrivateLast Round
Series C
Nov 12, 2024
Est. Valuation
$625M
Total Funding Raised
$297.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Impress operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was a Series C round in November 2024.
Impress is a clinics/outpatient services company that provides personalized teeth alignment solutions and digital monitoring for dental care.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, D2C Brands, Telemedicine, Patient Engagement
Business Model
B2C
Customer Profile
Hardware Sales, Services & Consulting, Payment Processing Fee
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Impress Comparables
Compare Impress with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rata | 77% | |
| SouSmile | 77% | |
| Zenyum | 76% |
For institutional investors. Book with your work email.
Impress Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 12, 2024 | ||||
| Series B | Jul 12, 2022 | ||||
| Series A | May 12, 2021 | ||||
| Seed | Oct 5, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Impress Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Linse Capital | Series A |
| Norgine Ventures | Series B |
| Claret Capital Partners | Series B |
| Hillhouse Investment | Series A |
| Media Digital Ventures | Series B |
| Bynd Venture Capital | Series A, Seed |
| UNIQA Ventures | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2026
Job posting indicates use of Rakuten's affiliate platform.
- Jul 1, 2026
Utilizes the Awin affiliate marketing platform.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenue_increased_byOct 28, 2026
Smile2impress Sl says it posts 32% revenue growth to €103 million in 2025.
- has_revenue_increased_byOct 27, 2026
Smile2impress Sl expects revenue to increase by 40% in 2026, reaching around €145 million.
- receives_financingOct 27, 2026
In May '21, Smile2impress Sl announces a $50M Series A round, with part of the financing earmarked to expand its presence across Europe.
For institutional investors. Book with your work email.
Impress Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Impress's valuation, stock price, and market status.
Is Impress a public or private company?
Impress is a private company.
What is the current stock price of Impress?
Impress is a private company, so its shares have no public market price. Caplight tracks Impress's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Impress worth (valuation)?
Impress's valuation is estimated at $625.0M based on funding round data.
Can I buy Impress stock?
Impress shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Impress's last funding round?
Impress's most recent funding round was Series C on November 12, 2024.
Who are the main investors in Impress?
Key investors in Impress include Trinity Capital, LBO France, CareCapital.
Will Impress IPO soon?
No public IPO plans have been announced for Impress.
How can I track Impress secondary market activity?
Caplight tracks bids, offers, and trades in Impress's shares on secondary markets.